JAK inhibition as a new treatment strategy for patients with COVID-19
Jin Huang1, Chi Zhou2, Jinniu Deng1
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan 430030, People's Republic of China.
Abstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic continues to spread globally. The rapid dispersion of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 drives an urgent need for effective treatments, especially for patients who develop severe pneumonia. The excessive and uncontrolled release of pro-inflammatory cytokines has proved to be an essential factor in the rapidity of disease progression, and some cytokines are significantly associated with adverse outcomes. Most of the upregulated cytokines signal through the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway. Therefore, blocking the exaggerated release of cytokines, including IL-2, IL-6, TNF-α, and IFNα/β/γ, by inhibiting JAK/STAT signaling will, presumably, offer favorable pharmacodynamics and present an attractive prospect. JAK inhibitors (JAKi) can also inhibit members of the numb-associated kinase (NAK) family, including AP2-associated kinase 1 (AAK1) and cyclin G-associated kinase (GAK), which regulate the angiotensin-converting enzyme 2 (ACE-2) transmembrane protein and are involved in host viral endocytosis. According to the data released from current clinical trials, JAKi treatment can effectively control the dysregulated cytokine storm and improve clinical outcomes regarding mortality, ICU admission, and discharge. There are still some concerns surrounding thromboembolic events, opportunistic infection such as herpes zoster virus reactivation, and repression of the host's type-I IFN-dependent immune repair for both viral and bacterial infection. However, the current JAKi clinical trials of COVID-19 raised no new safety concerns except a slightly increased risk of herpes virus infection. In the updated WHO guideline, Baricitinb is strongly recommended as an alternative to IL-6 receptor blockers, particularly in combination with corticosteroids, in patients with severe or critical COVID-19. Future studies will explore the application of JAKi to COVID-19 treatment in greater detail, such as the optimal timing and course of JAKi treatment, individualized medication strategies based on pharmacogenomics, and the effect of combined medications.
Insights
Janus kinase inhibitors (JAKi) effectively manage severe COVID-19 by controlling cytokine storms and improving patient outcomes. While generally safe, monitoring for infections like herpes zoster is advised.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, necessitating effective treatments for severe pneumonia.
- Uncontrolled pro-inflammatory cytokine release drives rapid disease progression and adverse outcomes in COVID-19.
- The Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway is a key signaling route for upregulated cytokines.
Purpose of the Study:
- To evaluate the efficacy of JAK inhibitors (JAKi) in managing the cytokine storm associated with severe COVID-19.
- To assess the impact of JAKi on clinical outcomes, including mortality, ICU admission, and discharge rates.
- To review the safety profile of JAKi in COVID-19 patients, including potential adverse events.
Main Methods:
- Analysis of data from current clinical trials investigating JAK inhibitors for COVID-19 treatment.
- Review of cytokine profiles and their association with disease severity and outcomes.
- Examination of the mechanism of action of JAKi, including their effects on cytokine signaling and viral endocytosis.
Main Results:
- JAK inhibitors effectively control the cytokine storm in severe COVID-19.
- Treatment with JAKi demonstrates significant improvements in mortality, ICU admission, and discharge rates.
- While generally safe, a slight increase in herpes virus infections was noted, but no new major safety concerns emerged.
Conclusions:
- JAK inhibitors represent a promising therapeutic strategy for severe COVID-19, offering favorable pharmacodynamics.
- Baricitinib is recommended by WHO guidelines as an alternative to IL-6 receptor blockers for severe/critical COVID-19, often with corticosteroids.
- Future research should focus on optimal JAKi treatment timing, duration, pharmacogenomics, and combination therapies.
Related Concept Videos
01:14Myocarditis III: Medical Management
02:34Inhibition of Cdk Activity
01:30Enzyme Inhibition
01:28Antimicrobial Effectiveness
01:13Controls in Experiments
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...